Burks Cynthia
Known title: DirectorCIK: 0001941449
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
WD-40 Declares Quarterly Dividend Amid Market Scrutiny. WD-40 has declared its regular quarterly dividend, a move that supports its profile as a consistent income stock. Recent market attention on the company coincides with its price trading near a key support level of $199.59. While analysts maintain a higher average price target, the stock currently reflects a valuation that investors are monitoring closely.
Transaction History
| INSP | ▲ Buy | Grant | 3,562 | $0 | 4/30/2026 | View on chart |
| WDFC | ▲ Buy | Grant | 612 | — | 12/12/2025 | View on chart |
| INSP | ▲ Buy | Grant | 1,266 | $0 | 5/1/2025 | View on chart |
| WDFC | ▲ Buy | Grant | 412 | — | 12/12/2024 | View on chart |
| INSP | ▲ Buy | Grant | 716 | $0 | 5/2/2024 | View on chart |
| WDFC | ▲ Buy | Grant | 406 | — | 12/12/2023 | View on chart |
| INSP | ▲ Buy | Grant | 669 | $0 | 4/27/2023 | View on chart |
| WDFC | ▲ Buy | Grant | 480 | — | 12/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Starts Coverage of Inspire Medical with Underweight
Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.
Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.